公开(公告)号：US20240002521A1

公开(公告)日：2024-01-04

申请号：US18253469

申请日：2021-11-19

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  INSTITUT JEAN PAOLI & IRENE CALMETTES ,  ALDERAAN BIOTECHNOLOGY ,  UNIVERSITE D'AIX MARSEILLE ,  UNIVERSITÉ DE PARIS ,  UNIVERSITE PARIS EST CRETEIL VAL DE MARNE ,  AL DE LA RECHERCHE SCIENTIFIQUE

发明人： Daniel OLIVE ,  Armand BENSUSSAN ,  Jérôme GIUSTINIANI ,  Anne MARIE-CARDINE ,  Amaud FOUSSAT ,  Jemila HOUACINE

IPC分类号： C07K16/28

CPC分类号： C07K16/2866 ,  C07K2317/21 ,  C07K2317/732

摘要： Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.

公开(公告)号：US11856093B2

公开(公告)日：2023-12-26

申请号：US17043300

申请日：2019-03-29

申请人： Centre National de la Recherche Scientifique ,  UNIVERSITÉ DE PARIS

发明人： Damián Pitalúa García ,  Iordanis Kerenedis

IPC分类号： H04L9/08 ,  G06N10/00

CPC分类号： H04L9/0852 ,  G06N10/00 ,  H04L2209/46 ,  H04L2209/50

摘要： A method for performing spacetime-constrained oblivious transfer between various laboratories of a first party A and various laboratories of a second party B. The method includes providing the spacetime-constrained oblivious transfer to satisfy various conditions. The method further includes encoding, by the laboratories of the first party A, various messages in a quantum state selected from various non-orthogonal quantum states. The method further includes transmitting, by the laboratories of the first party A, the quantum state to a first laboratory of the second party B. The method further includes applying, by the first laboratory of the second party B, a quantum measurement on the quantum state to obtain a classical measurement outcome. The method further includes transmitting, by the first laboratory of the second party B, the classical measurement outcome to the laboratories of the second party B.

公开(公告)号：US20230241057A1

公开(公告)日：2023-08-03

申请号：US17999910

申请日：2021-05-27

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE PARIS ,  UNIVERSITÉ PARIS XIII PARIS-NORD ,  CARDIOVASCULAR LAB S.P.A

发明人： Giuseppina CALIGIURI ,  Antonino NICOLETTI ,  Marta ANTONUCCI ,  Charles SKARBEK

IPC分类号： A61K31/496 ,  A61K31/5415 ,  A61K31/4025 ,  C07K16/18 ,  A61K31/165 ,  A61K31/343 ,  A61K31/787 ,  A61P7/02 ,  A61L31/10 ,  A61L31/16

CPC分类号： A61K31/496 ,  A61K31/5415 ,  A61K31/4025 ,  C07K16/18 ,  A61K31/165 ,  A61K31/343 ,  A61K31/787 ,  A61P7/02 ,  A61L31/10 ,  A61L31/16 ,  A61L2420/06 ,  A61L2300/42

摘要： The present invention relates to compounds for medical use in the treatment or in the prevention or in the diagnosis of arterial or venous thromboembolism.

公开(公告)号：US20230235408A1

公开(公告)日：2023-07-27

申请号：US18003535

申请日：2021-06-28

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  SORBONNE UNIVERSITÉ ,  UNIVERSITÉ DE PARIS

发明人： Franck PAGES ,  Jérôme GALON ,  Guy ZEITOUN ,  Amos KIRILOVSKY

IPC分类号： C12Q1/6886 ,  G01N33/574 ,  G01N33/569

CPC分类号： C12Q1/6886 ,  G01N33/57419 ,  G01N33/56972 ,  G01N2800/52 ,  C12Q1/6869

摘要： The inventors assessed in locally advanced rectal cancer whether a diagnostic biopsy-adapted Immunoscore (ISg) could predict response to neoadjuvant treatment (nT) and better define patients eligible to an organ preservation strategy (“Watch-and-Wait”). The inventors showed that ISB was an independent parameter, more informative than pre- (P

公开(公告)号：US20220341479A1

公开(公告)日：2022-10-27

申请号：US17262402

申请日：2019-07-22

申请人： PARIS SCIENCES ET LETTRES - QUARTIER LATIN ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS ,  SORBONNE UNIVERSITÉ ,  UNIVERSITÉ DE PARIS

发明人： Emmanuel SIEFERT ,  Benoît ROMAN ,  José BICO ,  Etienne REYSSAT

IPC分类号： F16F9/04

摘要： Pneumatic Structure and Associated Production Method
The structure (10) comprises an elastically deformable body (12) defining at least one network of internal cavities (14), each internal cavity (14) having a closed contour in at least one section of the internal cavity (14),
Each internal cavity (14) is able to be pressurized so as to make the elastically deformable body (12) pass from a rest configuration to at least one pressurized configuration,
In each pressurized configuration, the elastically deformable body (12) has a macroscopic metric that is distinct from its macroscopic metric in the rest position,
In each pressurized configuration, the radius of curvature of an outer surface of the elastically deformable body (12), considered regarding each internal cavity (14) adjacent to the outer surface, is greater than twice the size of the internal cavity (14) adjacent to the outer surface.

公开(公告)号：US11458194B2

公开(公告)日：2022-10-04

申请号：US16303705

申请日：2017-05-24

申请人： INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS ,  UNIVERSITÉ PARIS-SACLAY ,  UNIVERSITÉ DE PARIS

发明人： Frank Griscelli ,  Ali Turhan ,  Annelise Bennaceur Griscelli

IPC分类号： A61K35/545 ,  A61K31/19 ,  A61K45/06 ,  A61K39/00 ,  A61P35/00

摘要： The inventors have developed a metastatic 4T1 breast tumor model in BALB/c mice. They have shown that the vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher anti-tumoral response against breast cancer and inhibits metastasis development. They established that these responses are achieved only by the addition of valproic acid in the therapeutic regimen in comparison to the use ESCs or iPSCs alone. Thus, the inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to i) a population of pluripotent cells and ii) a compound selected from a group which activates MHC expression, as a combined preparation for use in a method for treating a subject suffering from a cancer, comprising a step of administering simultaneously, separately or sequentially to said subject a therapeutically amount thereof.

公开(公告)号：US20220259295A1

公开(公告)日：2022-08-18

申请号：US17620381

申请日：2020-06-19

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE PARIS ,  UNIVERSITÉ PARIS-SA-CLAY ,  UNIVERSITÉ PARIS XIII PARIS-NORD

发明人： Christian Kurts ,  Mirjam Meißner ,  Johannes Oldenburg ,  Thilo Albert ,  Janine Gotot

IPC分类号： C07K16/18 ,  A61P7/04

摘要： Protease nexin-1 (PN-1) is a member of the serine protease inhibitor (Serpin)-family, with thrombin as its main target. Current polyclonal and monoclonal antibodies against PN-1 frequently cross-react with Plasminogen activator inhibitor-1 (PAI-1), a structurally and functionally homologous Serpin. Herein the inventors develop inhibitory single-domain antibodies (VHHs) showing specific binding to both human (hPN-1) and murine (mPN-1) PN-1 and which de not cross-react with PAI-1. Importantly, all VHHs could block PN-1 activity in plasma as well as PN-1 released from activated platelets, one of the main sources of PN-1 during hemostasis. Thus, the present invention relates to anti-protease nexin-1 (PN-1) conformational single domain antibodies and uses thereof in particular in the therapeutic field for the treatment of haemorrhagic diseases.

公开(公告)号：US20220250057A1

公开(公告)日：2022-08-11

申请号：US17595723

申请日：2020-06-05

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS ,  SORBONNE UNIVERSITE ,  UNIVERSITÉ DE PARIS

发明人： Jean-luc AIDER ,  Mauricio HOYOS ,  Nathan JEGER-MADIOT

IPC分类号： B01L3/00

摘要： A microfluidic chip, in particular for a cell culture, the chip including a block made from biocompatible material, a passage channel made in the block for the passage of cells bathed in a liquid, in particular a nutrient liquid, a resonant cavity made in the block, connected to the passage channel and including walls for containing the cells originating from the passage channel, a generator generating acoustic waves capable of forming at least one cell aggregate in acoustic levitation in the resonant cavity, and at least one optical emitter capable of illuminating cells in the resonant cavity through at least one wall of the resonant cavity and simultaneous to the generation of acoustic waves in such a way as to structure the at least one aggregate by means of the optical exclusion technique.

公开(公告)号：US11407741B2

公开(公告)日：2022-08-09

申请号：US16650629

申请日：2018-09-26

申请人： UNIVERSITÉ DE PARIS ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  SORBONNE UNIVERSITE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

发明人： Etienne Jacotot ,  Elodie Bosc

IPC分类号： C07D405/12 ,  C07D207/16 ,  C07D401/12 ,  C07D417/14

摘要： The present invention relates to a compound of formula (I): wherein P1, P3, P4 and P5 are amino acid residues or amino acid like structures. The invention also relates to a compound of formula (I) for its use as a Caspase-2 inhibitor and for its therapeutical use. It also concerns the use of a compound of formula (I) as activity base probe to selectively detect Caspase-2 activity.

公开(公告)号：US11406631B2

公开(公告)日：2022-08-09

申请号：US17045049

申请日：2019-04-03

申请人： Universite de Bretagne Occidentale ,  Centre Hospitalier Regional Universitaire de Brest ,  Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre National de la Recherche Scientifique (CNRS) ,  Institut Curie ,  Université de Paris ,  Univ Paris XIII Paris-Nord Villetaneuse ,  Universite Paris-Saclay

发明人： Marc Blondel ,  Alicia Quillevere ,  Cécile Voisset ,  Maria José Lista ,  Robin Fahraeus ,  Chrysoula Daskalogianni ,  Rodrigo Prado-Martins ,  Marie-Paule Teulade-Fichou ,  Anton Granzhan ,  Claire Beauvineau ,  Oksana Reznichenko

IPC分类号： A61K31/4709 ,  A61P31/20 ,  A61P35/00 ,  A61K9/00 ,  A61K31/444 ,  A61K31/4745 ,  A61K31/506 ,  A61K45/06 ,  C07D401/14 ,  C07D471/04

摘要： The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2− and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.